Literature DB >> 16614986

Selective COX-2 inhibition reduces leukocyte sticking and improves the microcirculation in TNBS colitis.

Martin Kruschewski1, Tanja Anderson, Heinz J Buhr, Christoph Loddenkemper.   

Abstract

The role of cyclooxygenase-2 inhibitors in the course of experimental colitis is controversially discussed. The aim of this study was to evaluate leukocyte-endothelium interaction and colitis activity after applying the selective cyclooxygenase-2 inhibitor NS-398 in a rat trinitrobenzene sulfonic acid (TNBS) colitis model. The acute phase of TNBS colitis is characterized by a significant reduction of capillary blood flow, capillary density, diuresis, and weight and a significant increase in capillary permeability, leukocyte sticking, and hematocrit. Applying the selective cyclooxygenase-2 inhibitor NS-398 leads to a significant improvement of all microcirculatory parameters and clinical findings compared to the (untreated) colitis group. There are no histopathological differences between the individual colitis groups. Acute colitis is characterized by an extensive disturbance of microcirculation together with signs of systemic inflammatory response syndrome. These alterations are significantly improved by inhibiting cyclooxygenase-2. The results support the described correlation between cyclooxygenase activation and leukocyte-endothelium interaction. Moreover, they underscore the postulated relation between leukocyte-endothelium interaction and capillary blood flow.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16614986     DOI: 10.1007/s10620-006-3189-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  73 in total

1.  Functional capillary density: an indicator of tissue perfusion?

Authors:  D Nolte; H Zeintl; M Steinbauer; S Pickelmann; K Messmer
Journal:  Int J Microcirc Clin Exp       Date:  1995 Sep-Oct

2.  Effects of selective and unselective cyclooxygenase inhibitors on prostanoid release from various rat organs.

Authors:  I Tegeder; W Neupert; H Gühring; G Geisslinger
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

3.  Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease.

Authors:  Uma Mahadevan; Edward V Loftus; William J Tremaine; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2002-04       Impact factor: 10.864

4.  Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine.

Authors:  P Sharon; M Ligumsky; D Rachmilewitz; U Zor
Journal:  Gastroenterology       Date:  1978-10       Impact factor: 22.682

Review 5.  Animal models of intestinal inflammation: new insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease.

Authors:  S Wirtz; M F Neurath
Journal:  Int J Colorectal Dis       Date:  2000-06       Impact factor: 2.571

6.  Expression of leukocyte adhesion molecules by mucosal mononuclear phagocytes in inflammatory bowel disease.

Authors:  G Malizia; A Calabrese; M Cottone; M Raimondo; L K Trejdosiewicz; C J Smart; L Oliva; L Pagliaro
Journal:  Gastroenterology       Date:  1991-01       Impact factor: 22.682

7.  Adhesion molecules in inflammatory bowel disease.

Authors:  S C Jones; R E Banks; A Haidar; A J Gearing; I K Hemingway; S H Ibbotson; M F Dixon; A T Axon
Journal:  Gut       Date:  1995-05       Impact factor: 23.059

8.  The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease.

Authors:  Robin Matuk; Jonathan Crawford; Maria T Abreu; Stephan R Targan; Eric A Vasiliauskas; Konstantinos A Papadakis
Journal:  Inflamm Bowel Dis       Date:  2004-07       Impact factor: 5.325

9.  Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease.

Authors:  I I Singer; D W Kawka; S Schloemann; T Tessner; T Riehl; W F Stenson
Journal:  Gastroenterology       Date:  1998-08       Impact factor: 22.682

10.  Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial.

Authors:  L Biancone; C Tosti; A Geremia; D Fina; C Petruzziello; S Emerenziani; F Pallone
Journal:  Aliment Pharmacol Ther       Date:  2004-04-01       Impact factor: 8.171

View more
  1 in total

1.  Relationship between inflammation and tissue hypoxia in a mouse model of chronic colitis.

Authors:  Norman R Harris; Patsy R Carter; Amit Singh Yadav; Megan N Watts; Songlin Zhang; Melissa Kosloski-Davidson; Matthew B Grisham
Journal:  Inflamm Bowel Dis       Date:  2010-09-27       Impact factor: 5.325

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.